Almitas Capital LLC Design Therapeutics, Inc. Transaction History
Almitas Capital LLC
- $205 Million
- Q4 2024
A detailed history of Almitas Capital LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 1,323,667 shares of DSGN stock, worth $6.14 Million. This represents 3.98% of its overall portfolio holdings.
Number of Shares
1,323,667
Previous 1,323,667
-0.0%
Holding current value
$6.14 Million
Previous $7.12 Million
14.69%
% of portfolio
3.98%
Previous 3.32%
Shares
3 transactions
Others Institutions Holding DSGN
# of Institutions
97Shares Held
32.1MCall Options Held
4.6KPut Options Held
2.6K-
Sr One Capital Management, LP6.53MShares$30.3 Million14.99% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$19.6 Million3.42% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$10.7 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.06 Million0.72% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.86MShares$8.62 Million0.03% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $259M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...